The DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.
Randomized, Double-Blind Trial of Olanzapine Versus Placebo in Patients Prodromally Symptomatic for Psychosis
Abstract
OBJECTIVE: This study assessed the efficacy of olanzapine in delaying or preventing conversion to psychosis and reducing symptoms in people with prodromal symptoms of schizophrenia. METHOD: This randomized trial occurred at four North American clinics in the Prevention Through Risk Identification, Management, and Education project. Outpatients received olanzapine (5-15 mg/day, N=31) or placebo (N=29) during a 1-year double-blind treatment period and no treatment during a 1-year follow-up period. Efficacy measures included the conversion-to-psychosis rate and Scale of Prodromal Symptoms scores. RESULTS: During the treatment year, 16.1% of olanzapine patients and 37.9% of placebo patients experienced a conversion to psychosis, a nearly significant difference. The hazard of conversion among placebo patients was about 2.5 times that among olanzapine-treated patients, which also approached significance. In the follow-up year, the conversion rate did not differ significantly between groups. During treatment, the mean score for prodromal positive symptoms improved more in the olanzapine group than in the placebo group, and the mixed-model repeated-measures least-squares mean score showed significantly greater improvement between weeks 8 and 28 with olanzapine. The olanzapine patients gained significantly more weight (mean=8.79 kg, SD=9.05, versus mean=0.30 kg, SD=4.24). CONCLUSIONS: A significant treatment difference in the conversion-to-psychosis rate was not demonstrated. However, these results may be influenced by low power. The nearly significant differences suggest that olanzapine might reduce the conversion rate and delay onset of psychosis. Olanzapine was efficacious for positive prodromal symptoms but induced weight gain. Further treatment research in this phase of illness is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, clinical trials have failed so far to provide clear evidence that antipsychotics can prevent conversion to schizophrenia in at-risk individuals 63 .”
From Developmental timing and critical windows for the treatment of psychiatric disorders (2016) · cites this paper as [63]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
Simpson, G. M., B., M., B., G., Angus, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,265
A Rating Scale for Drug-Induced Akathisia
Barnes, T. R. E. (1989) · The British Journal of Psychiatry · doi:10.1192/bjp.154.5.672 · Cited by 2,179
The number needed to treat: a clinically useful measure of treatment effect
Cook, R. J., & Sackett, D. L. (1995) · BMJ · doi:10.1136/bmj.310.6977.452 · Cited by 1,885
Miller, T. J., McGlashan, T. H., Rosen, J. L., Cadenhead, K. S., Ventura, J., McFarlane, W. R., Perkins, D. O., Pearlson, G. D., & Woods, S. W. (2003) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a007040 · Cited by 1,800
Self-citationMeasurement of Premorbid Adjustment in Chronic Schizophrenia
Cannon-Spoor, H. E., Potkin, S. G., & Wyatt, R. J. (1982) · Schizophrenia Bulletin · doi:10.1093/schbul/8.3.470 · Cited by 1,220
McGorry, P. D., Yung, A. R., Phillips, L. J., Yuen, H. P., Francey, S., Cosgrave, E. M., Germano, D., Bravin, J., McDonald, T., Blair, A., et al. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.10.921 · Cited by 1,056
Global Assessment of Functioning
Hall, R. C. W. (1995) · Psychosomatics · doi:10.1016/s0033-3182(95)71666-8 · Cited by 975
Flagged first, then by citations
1 of the 30 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- McGlashan TH, 2001, Netherlands, Kluwer Academic, 135
- Guy, 1976, ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338
Cited by
Sorted by citations
Items 501–557 of 557
Díaz, N. E., Avezuela, N. R., Moliner, M. G., Fraile, J. C. F., & García‐Cabeza, I. (2010)
Schizophrenia: Blood-Serum-Plasma Metabolomics
Lista, S., Giegling, I., & Rujescu, D. (2014) · Advances in biological psychiatry · doi:10.1159/000358024
[The screening test for mitochondrial disease].
Oguro, N., & Momoi, M. Y. (2002) · PubMed
Klinische Prädiktion und Prävention von Psychosen
Ruhrmann, S., Paruch, J., & Klosterkötter, J. (2010) · Psychiatrie und Psychotherapie up2date · doi:10.1055/s-0030-1248504
INTERVENÇÃO PRECOCE NA PSICOSE Período Pré-psicótico
Coentre, R. M., Levy, P., & Figueira, M. L. (2010) · DOAJ (DOAJ: Directory of Open Access Journals) · doi:10.20344/amp.742
Godini, L., Lelli, L., Campone, B., Ciampi, E., Corsi, E., Ramella‐Cravaro, V., & Ballerini, A. (2016)
Artículo Monográfico Intervenciones psicosociales en la psicosis temprana
Fornells‐Ambrojo, M., & Craig, T. (2011)
Treatment of psychoses in children and adolescents
James, A. C., & McClellan, J. (2008) · Cambridge University Press eBooks · doi:10.1017/cbo9780511544392.058
Schizofrenia ad esordio in età evolutiva: aspetti clinici e interventi possibili
Pontillo, M., Armando, M., Coletti, M., Santonastaso, O., & Vicari, S. (2016) · QUADERNI DI PSICOTERAPIA COGNITIVA · doi:10.3280/qpc2016-039003
FORUM: EaRly INTERVENTION IN psychOsIs: clINIcal aNd EThIcal challENgEs
McGorry, P. D. (2008)
Inappropriate hemodynamic response in the individuals with at-risk mental state
Koike, S., 滝沢, 龍., 西村, 幸., 洋輔, 高., 岩白訓周, 嘉弘, 里., 荒木, 剛., & 清登, 笠. (2012) · 日本生物学的精神医学会誌 = Japanese journal of biological psychiatry · doi:10.11249/jsbpjjpp.23.1_61
(2007) · CNS Spectrums · doi:10.1017/s1092852900025931
Design and in vitro evaluation of mouth dissolving tablets olanzapine
Sharma, V. K., Singh, V., Juyal, D., & Rawat, G. (2015) · DOAJ (DOAJ: Directory of Open Access Journals)
Making Sense of Psychosis: Parental Attributions for Problem Behaviour in Recent Onset Psychosis
Robertson, D. (2008) · Griffith Research Online · doi:10.25904/1912/796
Stone, B. A., & Lepping, P. (2017) · Indian Journal of Psychiatry · doi:10.4103/psychiatry.indianjpsychiatry_59_16
Rowles, B. M., Hertzer, J. L., & Findling, R. L. (2012) · Wiley eBooks · doi:10.1002/9781119958338.ch10
Glenthøj, L. B., Albert, N., Christensen, F. H., Nordgaard, J., & Nordentoft, M. (2019) · Springer eBooks · doi:10.1007/978-3-030-17336-4_19
Lambert, M., & Naber, D. (2012) · doi:10.1007/978-1-908517-68-5_2
Behandlung unter besonderen Bedingungen (Modul 4c)
Gäebel, W., Hasan, A., & Falkai, P. (2019) · Springer eBooks · doi:10.1007/978-3-662-59380-6_7
Prevention and Early Intervention in At-Risk States for Developing Psychosis
Ruhrmann, S., Schultze‐Lutter, F., SCHIMMELMANN, B. G., & Klosterkötter, J. (2011) · Springer eBooks · doi:10.1007/978-94-007-0834-1_4
Future directions in risk research
Albert, N., Glenthøj, L. B., & Nordentoft, M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813201-2.00022-3
Differential diagnosis of autism spectrum disorder and early onset schizophrenia: two clinical cases
Martin, A. M., Stavropoulos, K. K. M., & Blacher, J. (2020) · Advances in Autism · doi:10.1108/aia-11-2019-0043
Prevention and early intervention in psychotic disorders
Bora, E., Jayaram, M., & Pantelis, C. (2020) · doi:10.1093/med/9780198713005.003.0063
Μούτσου, Ε., & Γεωργάκα, Ε. (2020) · Psychology the Journal of the Hellenic Psychological Society · doi:10.12681/psy_hps.23272
Negative Symptoms in Youth at Risk of Psychosis
Devoe, D. J. A. (2020) · doi:10.11575/prism/37975
Kapitel 8 Literaturverzeichnis
(2007) · Elsevier eBooks · doi:10.1016/b978-343724350-9.50010-4
Current awareness in human psychopharmacology
(2006) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.789
Psychoneurobiology Research and Personalized Treatment of Schizophrenia
Sumiyoshi, T. (2022) · MDPI eBooks · doi:10.3390/books978-3-0365-2858-8
(2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615372997.as04
(2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615372300.as04
Prepsychotic States and Prodromal Symptoms
McGorry, P. D., & Yung, A. R. (2015) · Springer eBooks · doi:10.1007/978-3-642-36172-2_262
CHILDREN WITH PRODROMAL SYMPTOMS OF PSYCHOSIS: Translating Research Into Clinical Practice
Mayanil, T., Adelsheim, S., & Blau, G. M. (2014) · JAACAP Connect · doi:10.62414/001c.92674
Ballon, J. S., Nunes, J. C., & Salaheldin, K. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as27
Chapter 4. Antipsychotic Drugs
(2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9798894551289.cd04
Ghalib, K., & Harper, G. P. (2009) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615378029.lg10
Chapter 12. Health Promotion and Prevention of Somatic Illnesses in Psychiatric Settings
Hackman, A. L., Hekler, E. B., & Dixon, L. B. (2009) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615378029.lg12
McGriff, J. A., McDonald, W. M., Duberstein, P. R., & Lyness, J. M. (2009) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615378029.lg11
Chapter 3. Prevention of Mood Disorders
Borba, C. P. C., & Druss, B. G. (2009) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615378029.lg03
Chapter 4. Prevention of Anxiety Disorders
Bienvenu, O. J., Siegel, D. J., & Ginsburg, G. S. (2009) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615378029.lg04
(2009) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615378029.index
Chapter 9. Prevention of Family Violence
Rogers, K., Baumgardner, B., Connors, K., Martens, P., & Kiser, L. J. (2009) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615378029.lg09
Chapter 2. Identifying and Understanding Risk Factors and Protective Factors in Clinical Practice
Shaffer, A., & Yates, T. M. (2009) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615378029.lg02
Chapter 7. Prevention of Alcohol and Drug Abuse
Powers, R. A. (2009) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615378029.lg07
Chapter 13. Prevention of Cigarette Smoking: Principles for Psychiatric Practice
Powers, R. A., & Compton, M. T. (2009) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615378029.lg13
Grunebaum, M. F., & Soleimani, L. (2009) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615378029.lg08
(2009) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615378029.fm01
Chapter 6. Applying Prevention Principles to Schizophrenia and Other Psychotic Disorders
Compton, M. T. (2009) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615378029.lg06
Chapter 5. Complementary and Alternative Medicine in the Prevention of Depression and Anxiety
Owen‐Smith, A. A., & Raison, C. L. (2009) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615378029.lg05
Early Intervention in Psychosis: A Brief Narrative Review
Agarwal, V., & Gairola, A. (2024) · Journal of Indian Association for Child and Adolescent Mental Health · doi:10.1177/09731342241299867
Ye, A., Zhang, D., Liu, X., Xu, L., Wei, Y., Cui, H., Zheng, W., Hong, Y., Zhao, J., Tang, Y., et al. (2025) · Schizophrenia Research · doi:10.1016/j.schres.2025.09.024
Chapter 7. Treatment of the Schizophrenia Prodrome
Cornblatt, B. A., Lencz, T., Smith, C. W., & Auther, A. M. (2007) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781585627080.lg07
Psychosocial interventions in early psychosis
Fornells‐Ambrojo, M., & Craig, T. (2011) · idUS (Universidad de Sevilla)
Molecular Neuroimaging, Pathophysiological Mechanisms, and Drug Discovery
McGuire, P. K. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0913-8_8
Gawłowska-Sawosz, M., Rabe‐Jabłońska, J., Pawełczyk, T., & Pawełczyk, A. M. (2010) · Psychiatria i Psychologia Kliniczna
Metadata
- Authors
- McGlashan, T. H., Zipursky, R. B., Perkins, D., Addington, J., Miller, T., Woods, S. W., A. Hawkins, K., E. Hoffman, R., Preda, A., Epstein, I., Addington, D., Lindborg, S., Trzaskoma, Q., Tohen, M., & Breier, A.
- Affiliations
- Yale University (US)
- ORCID
- Venue
- American Journal of Psychiatry
- Published
- 2006-05
- Volume
- 163
- Issue
- 5
- Pages
- 790-799
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2121366540
- Cited by
- 556
- References
- 30
- Citations by year
- 2026: 4 · 2025: 11 · 2024: 12 · 2023: 7 · 2022: 6 · 2021: 18 · 2020: 21 · 2019: 18 · 2018: 10 · 2017: 12 · 2016: 31 · 2015: 26 · 2014: 28 · 2013: 38 · 2012: 47
- FWCI
- 32.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- Funders
- Eli Lilly and Company
- University of Toronto
- National Institutes of Health (5r24mh054446-05)
- National Institute of Mental Health (K05 MH-01654, MH01654, 1 K23 MH01905, K23MH001905, R01MH067073, R01 MH-67073, R24-MH-54446, R02 MH-50557, K05MH001654)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Maternal Mental Health During Pregnancy and Postpartum
- Keywords
- olanzapine, transition to psychosis, weight gain, atypical antipsychotics
- MeSH terms
- Olanzapine, Adolescent, Ambulatory Care, Benzodiazepines, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Obesity, Placebos, Psychiatric Status Rating Scales, Schizophrenia, Schizophrenic Psychology, Severity of Illness Index, Antipsychotic Agents, Weight Gain, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
